Venetoclax in the Therapeutic Strategy for BPDCN Management.

ABSTRACT:

Background

Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials. However, several case reports have reported relapses after prolonged treatment, and development of resistance. To date, no study has investigated resistance to venetoclax in BPDCN. Therefore, we sought to investigate the mechanisms that trigger resistance during treatment.

Methods

We developed an in vitro model of chronic exposure of a BPDCN cell line to venetoclax that leads to resistance to the drug. We then characterized the resistant cell line using genomic and proteomic analyses and evaluated drug combinations to overcome the resistance.

Results

We found an upregulatio

SUBMITTER: Poussard M 

PROVIDER: S-EPMC12366441 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature